EXPLORE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION SCHEDULED FOR CARDIOVERSION

EXPLORE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION SCHEDULED FOR CARDIOVERSION

Cappato R., Ezekowitz M.D., Klein A.L., et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation // Eur. heart J. – 2014. Sep. 2. [Epub ahead of print].

Saved in:

Bibliographic Details
Format:	Article
Language:	Russian
Published:	Sklifosovsky Research Institute for Emergency Medicine, Public Healthcare Institution of Moscow Healthcare Department 2016-03-01
Series:	Неотложная медицинская помощь
Online Access:	https://www.jnmp.ru/jour/article/view/128
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

Rivaroxaban in stroke prevention in patients with non-valvular atrial fibrillation: what facts are important for the clinician?
by: I. S. Yavelov
Published: (2025-08-01)

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
by: Carlos Rubio-Terrés, et al.
Published: (2016-02-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020-01-01)

Safety and effectiveness of Rivaroxaban, Dabigatran and Apixaban in patients with non-valvular atrial fibrillation for stroke prophylaxis
by: Ceyda Tanoğlu, et al.
Published: (2025-07-01)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015-12-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

Left Atrial Thrombosis before Catheter Ablation or Cardioversion in Patients with Non-valvular Atrial Fibrillation or Atrial Flutter: what Risk Score is Most Informative?
by: I. A. Zaigraev, et al.
Published: (2023-05-01)

PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015-12-01)

Ogilvie’s Syndrome following Cardioversion for Atrial Fibrillation
by: Moh’d Al-Halawani, et al.
Published: (2014-01-01)

Population pharmacokinetic analysis of rivaroxaban in healthy volunteers and patients with radiofrequency ablation of non-valvular atrial fibrillation in China
by: Fangfang Gu, et al.
Published: (2025-05-01)

Factors associated with successful electrical cardioversion for atrial fibrillation
by: Naoya Kataoka, et al.
Published: (2025-08-01)

Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban
by: Iwona Gorczyca, et al.
Published: (2020-01-01)

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE
by: L. E. Kuvshinova, et al.
Published: (2015-09-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

Cost-effectiveness of direct oral anticoagulants in non-valvular atrial fibrillation
by: Inigo Gorostiza, et al.
Published: (2025-01-01)

Metabolic therapy effects on cardioversion results in persistent atrial fibrillation
by: A. A. Kotlyarov, et al.
Published: (2008-06-01)

CARDIOVERSION WITH BI- AND MONOPHASE DEFIBRILLATORS IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION
by: V. A. Lusov, et al.
Published: (2010-02-01)

Utilization and Predictors of Electrical Cardioversion in Patients Hospitalized for Atrial Fibrillation
by: Yogita M. Rochlani, et al.
Published: (2016-01-01)

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
by: article Editorial
Published: (2022-03-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Oral anticoagulation in patients with hypertrophic cardiomyopathy and non‐valvular atrial fibrillation in Japan
by: Hiroaki Kitaoka, et al.
Published: (2025-02-01)

Atrial fibrillation in elderly patients. Features of using rivaroxaban
by: A. D. Erlikh
Published: (2020-06-01)

Association of iron deficiency with atrial fibrillation recurrence after pharmacological cardioversion
by: M. Kh. Valeev, et al.
Published: (2023-07-01)

Value of transoesophageal echocardiography-guided approach to electrical cardioversion of atrial fibrillation
by: O. S. Kalashnikovа
Published: (2013-06-01)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
by: article Editorial
Published: (2015-11-01)

Prevalence, morphologic characteristic and predictors of organization of atrial auricle thrombi four weeks after anticoagulant preparation to scheduled electrical cardioversion of atrial fibrillation
by: Kalashnykova O.S.
Published: (2013-10-01)

Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?
by: N. N. Kryukov, et al.
Published: (2019-02-01)

Anticoagulation in Atrial Fibrillation With Valvular Heart Disease
by: Ana Catarina Fonseca, et al.
Published: (2025-02-01)

THE USE OF ATORVASTATIN FOR THE PREVENTION OF RECURRENT ATRIAL FIBRILLATION AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: S. N. Tereshchenko, et al.
Published: (2016-01-01)

SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT
by: E. A. Drozdova
Published: (2015-09-01)

NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE
by: E. P. Panchenko
Published: (2015-12-01)

What Governs Immediate or Delayed Cardioversion of Atrial Fibrillation by Direct Current Shock?
by: Amar T. AL-Hamdi, et al.
Published: (2024-12-01)

Ibutilide for the Cardioversion of Paroxysmal Atrial Fibrillation during Radiofrequency Ablation of Supraventricular Tachycardias
by: Kostas Polymeropoulos, et al.
Published: (2011-01-01)

Investigation of predictive parameters for recurrence in patients undergoing electrical cardioversion for atrial fibrillation
by: Levent Pay, et al.
Published: (2025-04-01)

Comparison of Angiotensin Converting Enzyme Inhibitors and Beta Blockers in Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion
by: Timuçin Altın, et al.
Published: (2007-12-01)

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN
by: I. S. Yavelov
Published: (2016-07-01)

Increased direct oral anticoagulant use and event rates in non-valvular atrial fibrillation: a nationwide retrospective registry study in Sweden
by: Bo Norrving, et al.
Published: (2025-07-01)

FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW
by: S. A. Zenin, et al.
Published: (2015-09-01)